Results 41 to 50 of about 13,535 (197)

Combined analysis of 16S rDNA sequencing and metabolomics to find biomarkers of drug-induced liver injury

open access: yesScientific Reports, 2023
Drug induced liver injury (DILI) is a kind of liver dysfunction which caused by drugs, and gut microbiota could affect liver injury. However, the relationship between gut microbiota and its metabolites in DILI patients is not clear.
Kaini He   +4 more
doaj   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo   +4 more
wiley   +1 more source

Hepatic macrophages in drug-induced liver injury

open access: yesLiver Research, 2019
Drug-induced liver injury (DILI) is a major public health concern. Intrinsic DILI, for example, acetaminophen overdose accounts for half of acute liver failure in the United States.
Zhao Shan, Cynthia Ju
doaj   +1 more source

Hepatocyte DDX3X protects against drug-induced acute liver injury via controlling stress granule formation and oxidative stress

open access: yesCell Death and Disease, 2023
Drug-induced liver injury (DILI) is the leading cause of acute liver failure (ALF). Continuous and prolonged hepatic cellular oxidative stress and liver inflammatory stimuli are key signatures of DILI.
Tingting Luo   +16 more
doaj   +1 more source

Drug-induced liver injury: A primer for cardiologists

open access: yesJournal of Clinical and Preventive Cardiology, 2022
Although drug-induced liver injury (DILI) is an uncommon diagnosis, it is an important cause of morbidity and mortality in hepatology practice. A timely diagnosis of DILI is important to stop causative drugs and keeping a high index of suspicion is ...
Narendra Singh Choudhary   +4 more
doaj   +1 more source

Lessons Learnt Delivering a Novel Infectious Diseases National Training Programme to Timor-Leste’s Primary Care Workforce

open access: yesAnnals of Global Health
Background and Objectives: Timor-Leste is a lower-middle-income country in Southeast Asia. To control the significant local threat from infectious diseases, it is imperative to strengthen the knowledge and practice capabilities of the primary care ...
Robert Hammond   +14 more
doaj   +1 more source

Polydatin Alleviates APAP‐Induced Hepatotoxicity by Targeting C/EBPβ to Suppress the NLRP3 Inflammasome Signaling Pathway

open access: yesiNew Medicine, EarlyView.
PD alleviates APAP‐induced ALI by inhibiting the NLRP3 inflammasome signaling pathway. C/EBPβ is identified as a direct target via multimethod validation. PD promotes the deacetylation of C/EBPβ via Sirt1. The Sirt1/C/EBPβ/NLRP3 signaling axis is defined for PD's hepatoprotective effect.
Tian‐Yu Yang   +6 more
wiley   +1 more source

The Influence of Regional Government and Community Participation on the Development of Spiritual Tourism in Pante Makasar, Timor-Leste

open access: yesInternational Journal of Home Economics, Hospitality and Allied Research
This study examines the role of government and community participation in the development of spiritual tourism in Pante Makassar, Oe-Cusse Municipality, Timor-Leste.
Cevat Tosun   +2 more
doaj   +1 more source

Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures

open access: yesFrontiers in Pharmacology, 2020
Drug-induced liver injury (DILI) is one of the major reasons for termination of drug development. Due to the importance of predicting DILI in early phases of drug development, diverse in silico models have been developed to filter out DILI-causing ...
Hyun Kil Shin   +7 more
doaj   +1 more source

Impact of cystic fibrosis transmembrane conductance regulator modulator therapies on liver stiffness and liver enzymes: An observational perspective single‐center cohort study

open access: yesJPGN Reports, EarlyView.
Abstract Objectives The efficacy of cystic fibrosis transmembrane conductance regulator (CFTR)‐modulator therapies in preventing or ameliorating cystic fibrosis liver disease (CFLD) by correcting CFTR in cholangiocytes is not well‐documented. This study aimed to assess liver function during CFTR‐modulators.
Laura Giugliano   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy